HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: In July 2014, the FDA approved Belinostat (Beleodaq®) as a third HDAC inhibitor, to treat patients with relapsed or refractory PTCL, and which has an overall response rate of 25.8% [8].